MedImmune has opened a new, state-of-the-art pilot lab facility at its Gaithersburg site headquarters. The facility features the latest equipment and process automation systems and will support the company's clinical product pipeline with additional capacity and flexibility.
MedImmune, David M. Mott, president and chief executive officer, stated, "Completing this new facility is an important milestone, signaling our continued growth and success as a world-class biopharmaceuticals company. The opening of this facility, alongside the expansion work underway on our new biologics facility in Frederick, Maryland, reaffirms our leadership role within the state's biotechnology industry and demonstrates our ongoing commitment to the region."
The new pilot lab's 5,000 liters of bioreactor capacity increases production capabilities four-fold. The expanded facility enables the company to produce clinical trial materials at a greater scale and in larger quantities, helping with the testing of potential new products.
"This substantial increase in MedImmune's clinical production infrastructure supports our robust pipeline of product candidates," said Gail Folena-Wasserman, Ph.D., senior vice president, development. "The pilot lab facility is intended to meet our current and future needs, not just through its increased capacity but also through design flexibility, which efficiently allows us to produce multiple clinical products in the same space. We can drive efficiency and meet rigorous quality standards by incorporating the latest technology, including an advanced process control system."
Magazine
